Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Travere Therapeutics, Inc. | ex322-1231202010k.htm |
| EX-32.1 - EX-32.1 - Travere Therapeutics, Inc. | ex321-1231202010k.htm |
| EX-31.2 - EX-31.2 - Travere Therapeutics, Inc. | ex312-1231202010k.htm |
| EX-31.1 - EX-31.1 - Travere Therapeutics, Inc. | ex311-1231202010k.htm |
| EX-21.1 - EX-21.1 - Travere Therapeutics, Inc. | ex211-1231202010k.htm |
| EX-10.38 - EX-10.38 - Travere Therapeutics, Inc. | ex1038-1231202010k.htm |
| EX-4.2 - EX-4.2 - Travere Therapeutics, Inc. | ex42-1231202010k.htm |
| 10-K - 10-K - Travere Therapeutics, Inc. | rtrx-20201231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Travere Therapeutics, Inc.
San Diego, California
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-227182, 333-202861, and 333-198648) and Form S-8 (Nos. 333-240222, 333-232857, 333-224848, 333-218582, 333-213599, 333-206510 and 333-200224) of Travere Therapeutics, Inc. (“the Company”) of our reports dated March 1, 2021, relating to the consolidated financial statements, and the effectiveness of the Company’s internal control over financial reporting, which appear in this Form 10-K.
/s/ BDO USA, LLP
San Diego, California
March 1, 2021